Drug Enforcement Administration

The Drug Enforcement Administration (DEA) is a United States federal agency that administers and enforces the Controlled Substances Act. It places compounds onto federal schedules, moves them between schedules, and assigns each controlled substance a numeric drug code used in tracking and regulatory compliance.

The DEA is not a scientific body — it makes scheduling decisions in consultation with the Department of Health and Human Services, which supplies a medical and scientific evaluation, but the final determination is the DEA's. Its authority is strictly domestic: a DEA schedule describes legal status within the United States only.

What it means in practice

The Controlled Substances Act organises controlled substances into five schedules. Schedule I is the most restrictive tier, prohibiting ordinary prescribing and sharply limiting research access; Schedule V is the least. Placement on a schedule determines what authorisation is needed to possess, prescribe, manufacture, or study a compound.

The DEA can add a substance through formal rulemaking or place it temporarily into Schedule I while full rulemaking proceeds. Rescheduling requires a petition, a scientific and medical evaluation from the Department of Health and Human Services, and a DEA final determination.

Every scheduled substance also receives a numeric drug code — a DEA administrative identifier used for manufacturing quotas, import and export permits, and record-keeping. It carries no information about pharmacology or therapeutic value.

How jurisdictions vary

DEA scheduling operates under U.S. federal law and carries no effect outside the United States. A compound that is Schedule I domestically may be authorised for medical use in Canada, assigned to a different tier in Australia, or governed by a distinct regulatory framework across the European Union.

Drug control obligations flow from three United Nations treaties, but each signatory state implements those obligations through its own national legislation. The schedule numbering in those treaties also differs from the Controlled Substances Act: a Schedule I in one system is not the equivalent of Schedule I in another.

Within the United States, individual states may maintain scheduling laws that diverge from the federal framework in either direction.

What is contested

The Schedule I designation turns partly on the statutory phrase no currently accepted medical use in treatment in the United States. This is a legal test, not a finding about clinical evidence. Several compounds that carry Schedule I status have also been enrolled in approved clinical trials or received regulatory designations indicating clinical promise, creating a documented gap between legal classification and the research record.

The criteria for meeting or exiting that threshold, and the respective roles of the DEA and the Department of Health and Human Services in rescheduling decisions, have been contested in administrative and judicial proceedings. This entry records that the gap exists; resolving it is outside the scope of a vocabulary reference.

Scope and currency

This entry is general encyclopedic background, not legal advice, and does not describe the law in any particular place, including the United States. Drug law changes through legislation, rulemaking, and court decision, and this entry may not reflect the current position.

Readers should consult the Legal status section on each substance page, which carries its own jurisdiction, date, and cited source. This entry states the position as of 24 August 2026.